Group 1 - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology [2] - The company utilizes its in-house precision medicine platform, SNÅP, for rapid and precise drug design, predicting genetic alterations that may cause resistance to existing therapies [2] - Tyra's lead product, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor designed to minimize toxicities associated with other FGFR inhibitors [2] Group 2 - Current clinical development plans for dabogratinib include studies for intermediate risk non-muscle invasive bladder cancer, pediatric achondroplasia, and potential future studies for metastatic urothelial cancer [2] - Tyra is also developing TYRA-430, an oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma [2] - The company will participate in investor events, including a virtual fireside chat on August 21, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [1]

Company Overview - Kennametal Inc. is an industrial technology leader with over 85 years of experience, focusing on materials science, tooling, and wear-resistant solutions [1] - The company serves customers in various sectors including aerospace and defense, earthworks, energy, general engineering, and transportation [1] - Kennametal employs approximately 8,100 individuals and operates in nearly 100 countries [1] Financial Performance - In fiscal 2025, Kennametal generated nearly $2 billion in revenues [1] Upcoming Events - Kennametal will attend the Morgan Stanley 13th Annual Laguna Conference on September 10, 2025 [1] - Key attendees from Kennametal include Sanjay Chowbey (President and CEO), Patrick Watson (CFO), and Michael Pici (VP, Investor Relations) [1]

Company Overview - MillerKnoll, Inc. is a growth-oriented small-cap value company operating in the industrial and consumer sectors, formed from the merger of two modern design icons, Herman Miller and Knoll [5] - The company offers a diverse portfolio of furniture and accessories for both commercial and residential spaces, including brands like Colebrook Bosson Saunders, DatesWeiser, DWR, Edelman, Geiger, HAY, HOLLY HUNT, Knoll Textiles, Maharam, Muuto, NaughtOne, and Spinneybeck | FilzFelt [5] - In fiscal year 2025, MillerKnoll generated net sales of $3.7 billion [5] Upcoming Financial Results - MillerKnoll will release its first quarter fiscal 2026 results on September 23, 2025, after market close [1] - A conference call and webcast to discuss the financial and operational results will take place at 5:00 p.m. Eastern time on the same day [1][3] - Investors can access the press release and supporting materials on the company's investor relations website [2]

Core Insights - Datadog, Inc. has achieved 'In Process' status for GovRAMP High Authorization, emphasizing its commitment to secure observability for the public sector [1][2] - This status allows Datadog for Government to support mission-critical workloads and sensitive data in regulated environments, facilitating digital transformation for state, local, and educational IT teams [2][3] Company Overview - Datadog is a monitoring and security platform for cloud applications, providing a unified, real-time observability and security solution across various technology stacks [5] - The platform integrates infrastructure monitoring, application performance monitoring, log management, user experience monitoring, and cloud security [5] Industry Context - Modern state, local, and educational organizations are navigating complex hybrid, multi-cloud, and edge environments while aiming to enhance public service delivery [4] - GovRAMP provides a standardized security framework for public sector organizations to evaluate cloud services against NIST 800-53 Rev. 5 controls, ensuring enhanced security and continuous monitoring [3]

The equity market is a powerful mechanism as daily fluctuations in price get aggregated to incredible wealth creation or destruction over the long term. Pacifica Yield aims to pursue long-term wealth creation with a focus on undervalued yet high-growth companies, high-dividend tickers, REITs, and green energy firms.Analyst’s Disclosure:I/we have a beneficial long position in the shares of CWEN.A either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my o ...

Group 1 - The author has a background in private credit and commercial real estate (CRE) mezzanine financing, indicating expertise in financial analysis and investment strategies [1] - The author has collaborated with prominent CRE developers, suggesting a strong network and experience in the real estate sector [1] - The author is a fluent Mandarin speaker, which may provide advantages in understanding Asian markets and investment opportunities [1] Group 2 - The article expresses personal opinions and does not represent any business relationship with mentioned companies, ensuring an independent perspective [2] - The content is based on personal research and experiences, highlighting the subjective nature of the analysis presented [3] - The article emphasizes that past performance does not guarantee future results, which is a common disclaimer in investment discussions [4]

Southfield, Michigan, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) has been named one of PEOPLE Magazine’s 100 Companies That Care® by Great Place To Work® and PEOPLE magazine for the fourth consecutive year. Credit Acceptance was ranked 44th among the 100 companies that made the list, up 15 spots from last year. “Being named a 'Company That Cares' is an incredible honor because it reflects the heart ...

Core Viewpoint - Invivyd, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the shares sold at the public offering price [1][3]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1]. - Cantor is acting as the sole book-running manager for the offering [2]. - The offering will be conducted under a shelf registration statement filed with the SEC, which was declared effective on October 5, 2022 [4]. Group 2: Use of Proceeds - Invivyd plans to use the net proceeds from the offering for trial protocol development, advancement of the VYD2311 clinical program, and research related to its pipeline programs, including RSV and measles [3]. - Additional uses of the proceeds include efforts related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, as well as general corporate purposes [3]. Group 3: Company Background - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [7]. - The company utilizes a proprietary technology platform to develop and adapt antibodies, and received emergency use authorization for a monoclonal antibody in March 2024 [7].

Core Insights - Rhythm Pharmaceuticals has received acceptance for its supplemental New Drug Application (sNDA) for setmelanotide from the U.S. FDA, with a PDUFA goal date set for December 20, 2025, indicating a priority review status [1] - The European Medicines Agency (EMA) has also validated a Type II variation submission for setmelanotide for the treatment of acquired hypothalamic obesity, with the review process initiated on August 16, 2025 [2] - Setmelanotide is already approved for other obesity-related conditions and is a melanocortin-4 receptor (MC4R) agonist, highlighting its potential in treating rare neuroendocrine diseases [3] Company Developments - Rhythm Pharmaceuticals will host an event titled "Commercial Readiness for Acquired Hypothalamic Obesity" on September 24, 2025, to discuss U.S. launch plans and the urgent need for treatment in this patient population [5] - The company emphasizes its commitment to expediting the availability of setmelanotide for patients suffering from acquired hypothalamic obesity, which presents unique challenges compared to general obesity [4] Clinical Trial Insights - The pivotal Phase 3 TRANSCEND trial involved 120 patients and demonstrated a statistically significant -19.8% placebo-adjusted reduction in body mass index (BMI) after 52 weeks of treatment with setmelanotide [4] - In the TRANSCEND trial, participants on setmelanotide achieved a -16.5% reduction in mean BMI compared to a +3.3% increase in the placebo group, with significant results across both adult and pediatric populations [4] Market Potential - Rhythm estimates that there are between 5,000 to 10,000 individuals in the U.S. and 3,500 to 10,000 in the EU living with acquired hypothalamic obesity, indicating a targeted market for setmelanotide [10]

MICHIGAN CITY, Ind., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Horizon Bancorp, Inc. (NASDAQ: HBNC) (“Horizon”), the parent company of Horizon Bank, announced today that it has launched an underwritten public offering of shares of its common stock (the “Offering”). Horizon expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering. Horizon intends to use the net proceeds from the Offering for general corporate purposes, including in s ...